Validation of Hepatoma Arterial Embolization Prognostic Score in Egyptian Patients

Samar Atef Sebaweh Mohammed;

Abstract


SUMMARY
H
CC is the sixth most common malignancy and the third most common cause of cancer related death. Since HCC usually develops in a damaged liver, the prognosis of HCC depends not only on tumor progression but also on the degree of liver dysfunction. In Egypt, liver cancer forms 23.81 of the total malignancies. HCC constitutes 70.48% of all liver tumors among Egyptians.
Chemoembolization (TACE) is the most widely used primary treatment for unresectable HCC and the recommended first line-therapy for patients at intermediate stage of the disease.
In contrast to other cancers, the prognosis of patients with HCC is not solely related to tumour stage. Accordingly, different prognostic systems assessing liver function and tumour stage have been developed such as the Okuda staging, CLIP score and the BCLC. The previous staging systems have been developed for the classification of patients with HCC, but none have been specifically developed to predict outcomes of therapy for HCC. Previous studies have compared staging systems for their ability to predict the survival of patients treated with TACE, but there is no evidence which is best.


Other data

Title Validation of Hepatoma Arterial Embolization Prognostic Score in Egyptian Patients
Other Titles التحقق من صحة المعدل التنبؤى للمرضى المصريين الذين خضعوا للحقن الشريانى للبؤر الكبدية
Authors Samar Atef Sebaweh Mohammed
Issue Date 2017

Attached Files

File SizeFormat
J3343.pdf157.82 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 2 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.